DIVI'S LABORATORIES LTD. - 532488 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- M Satish ChoudhuryDesignation :- Company Secretary and Compliance Officer DIVI'S LABORATORIES LTD. - 532488 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We hereby inform you that SEBI has passed an Impounding Order cum Show Cause notice bearing no. WTM/GM/IVD/14/2020-21 dated 01 July, 2020 against Mr. L. Kishore Babu, Chief Financial Officer of the Company and others, for alleged charges of Insider Trading in the securities of the Company during July, 2017. Mr. L. Kishore Babu has informed that he is seeking legal advice and will respond to above referred Order. This is for your information and records. DIVI'S LABORATORIES LTD. - 532488 - Submission Of Half Yearly Disclosure On Related Party Transactions For The Half Year Ended 31 March, 2020
Pursuant to Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards, for the half year ended 31 March, 2020. DIVI'S LABORATORIES LTD. - 532488 - Closure of Trading Window
Pursuant to the Company''s Code of Conduct to Regulate, Monitor and Report Trading by Insiders and Designated Persons and the SEBI (Prohibition of Insider Trading) Regulations, 2015, we hereby inform you that the Trading Window for dealing in securities of the Company shall remain closed for Insiders and Designated Persons of the Company from 01 July, 2020 till 48 hours after the declaration of Unaudited Financial Results for the quarter ended 30 June, 2020. The date of Board Meeting for declaration of the financial results of the Company for the quarter ended 30 June, 2020 will be intimated in due course. This is for your information and records. DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copies of notice to shareholders of the Company intimating that equity shares in respect of which dividend remain unclaimed for seven consecutive years would be transferred to Investor Education and Protection Fund (IEPF) Authority. This notice was published on 20 June, 2020 in the following newspapers: Financial Express (English Daily) Andhra Prabha (Telugu Daily)
Buy Divis Laboratories target of Rs 2700: Sharekhan
Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 2700 in its research report dated June 08, 2020. DIVI'S LABORATORIES LTD. - 532488 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31 March, 2020 DIVI'S LABORATORIES LTD. - 532488 - Audited Financial Results For The Quarter And Year Ended 31 March, 2020
Further to our letter dated 30 May, 2020, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 06 June, 2020 has approved the Audited Financial Results for the quarter and year ended 31 March, 2020. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: 1. Statement of Audited Standalone Financial Results for the quarter and year ended 31 March, 2020 and Auditors' Report thereon; 2. Statement of Audited Consolidated Financial Results for the quarter and year ended 31 March, 2020 and Auditors' Report thereon; 3. Declaration regarding Audit Reports with unmodified opinion; and 4. Press Release on the said Financial Results of the Company.
